Study of the Platelet Function During the Last Month of Pregnancy
The objective is to compare women's platelet answer in the last month of pregnancy to women old enough to procreate, no pregnancy and without hormonal treatment.
The hypothesis of research is that the decrease of platelet answer in pregnant women could not only limit the occurence of embolic accidents but also explain the lowest incidence of the arterial thrombosis in comparison with the venous thrombosis.
調査の概要
詳細な説明
This is a monocentric study comparing a group of pregnant women and a group of "no pregnancy" women.
The goal of the present study is to determine the impact of pregnancy on platelet function. For this, the study propose to explore, in women in the last month of pregnancy, the ability of platelets to aggregate after activation by strong agonists but also their ability to adhere to a matrix and form thrombies.
The study will include 30 pregnant and 30 "no pregnancy" control women, of childbearing age and not taking hormone therapy. From a blood sample, two types of examination will be implemented:
A) In whole blood, we will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed.
B) In washed platelets and whole blood, we shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Toulouse、フランス
- University Hospital of Toulouse
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Signature of the form of consent
Absence of any physical or psychic pathology which can interfere with the normal realization of the study
- Group1 : Women in the last month of pregnancy
- Group 2 : Women old enough to procreate, no pregnancy and without hormonal treatment
Exclusion Criteria:
- Thrombopenia (platelet numeration < 120 000 / mm3),
- Gestational diabet,
- Hormonal treatment : oestrogen-progestagen, progestagen, Selective Estrogen Receptor Modulator (SERM), inductors of ovulation,
- Anticoagulant and any medication which can intervene on the platelet function (AINS, antidepressants)
- Personal history of thromboembolic accident venous or arterial,
- Personal history of haemostasis disease
- Personal history of hepatic or renal disease
- Personal history of autoimmune disease.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
- 割り当て：非ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Pregnancy
Blood sample
|
In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made. In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed.
他の名前：
|
|
実験的：No pregnancy
Blood sample
|
In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made. In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
surface covered by platelets
時間枠：baseline
|
Percentage of surface covered by platelets (using the software Metamorph)
|
baseline
|
|
Volume of thrombies
時間枠：baseline
|
Total volume of thrombies in μm3 (using the software Metamorph)
|
baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Platelet aggregation
時間枠：baseline
|
Percentage of platelet aggregation (whole blood and washed platelets)
|
baseline
|
|
chemokine Platelet Factor 4
時間枠：baseline
|
Quantity of the chemokine Platelet Factor 4 (PF4) (IU/ml) secreted by the granules after activation by these agonists (washed platelets)
|
baseline
|
|
Thromboglobulin
時間枠：baseline
|
Quantity of thromboglobulin (in ng / ml) secreted by the granules after activation by these agonists (washed platelets)
|
baseline
|
協力者と研究者
捜査官
- 主任研究者：PARANT Olivier, MD PhD、University Hospital, Toulouse
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Blood sampleの臨床試験
-
University of UtahAlbert Einstein College of Medicine; University of California, San Francisco; National Human Genome... と他の協力者完了新生児スクリーニング
-
Ischemia Care LLC完了虚血性脳卒中 | 心房細動 | 血栓性脳卒中 | 一過性脳虚血発作 | 心塞栓性脳卒中 | 脳底動脈の脳卒中 | 一過性脳血管イベントアメリカ
-
Applied Science & Performance Institute完了
-
Bedford Hospital NHS TrustAnglia Ruskin Universityわからない